- Last Updated: Thursday, 16 February 2017 11:48
- Hits: 577
PENTA-ID stems from the need to integrate the expertise acquired by PENTA in more than 20 years of successful activity and the need for new studies in other paediatric infectious diseases.
The network benefits from international recognition, wide geographical representativeness, very high quality research, an outstanding track record and diversified public and private funding.
It has been recognised as a Level 1 network for paediatric infectious disease in Europe by the European networks of paediatric research at the European Medicines Agency (EnprEMA).
Its activities vary from clinical trials, to cohort studies and training. It is currently developing a portfolio of clinical trials in antimicrobials in children, including antibiotics, antivirals and antifungals.